Drug interactions
Belzutifan + Exemestane
Severity: Moderate
Belzutifan and Exemestane: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Belzutifan is a CYP3A4 inducer and may lower exemestane concentrations. Reduced exposure could diminish the estrogen-suppressing effect of exemestane in breast cancer treatment.
What this interaction means in plain words
Belzutifan and Exemestane can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Belzutifan belongs to Miscellaneous; Exemestane belongs to Oncology.
Why it happens
Induction of CYP3A4 by belzutifan increases exemestane metabolism.
What to do
Monitor for reduced exemestane efficacy. Exemestane labeling suggests considering a higher dose (50 mg daily) with strong CYP3A4 inducers; consider alternative if loss of response is suspected.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Belzutifan and Exemestane, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Exemestane
Other interactions of Belzutifan
Frequently asked questions
Can I take Belzutifan with Exemestane?
MediHelp rates the interaction as moderate. Belzutifan and Exemestane can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Belzutifan is a CYP3A4 inducer and may lower exemestane concentrations. Reduced exposure could diminish the estrogen-suppressing effect of exemestane in breast cancer treatment.
How serious is the interaction between Belzutifan and Exemestane?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for reduced exemestane efficacy. Exemestane labeling suggests considering a higher dose (50 mg daily) with strong CYP3A4 inducers; consider alternative if loss of response is suspected.
What other medicines interact with Exemestane?
MediHelp also lists interactions of Exemestane with, for example, Bazedoxifene-conjugated estrogens, Desogestrel-ethinyl estradiol, Estradiol. The full list is on the Exemestane page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
